We have shown recently the possibility of generating effector cell preparations enriched with CD56+ lymphocytes, NK and NKT-like, by ex vivo expansion of peripheral blood mononuclear cells (PBMC) from patients with ovarian cancer (FAPESP 2006/04900-2). The current project proposes to evaluate the receptor repertoire (inhibitory receptors: KIR2DL1, KIR2DL2/3 and KIR3DL1 and activating receptors: NKp30, NKp44, NKp46, NKG2D and DNAM-1) and functional integrity (CD107a molecule expression and cytotoxicity against primary neoplasm cells) of the NK and NKT-like lymphocytes from patients with ovarian neoplasm, before and after the ex vivo expansion of CD56+ cells. The experimental design will allow the evaluation of effector cell subtypes independently, and to take into account the clinical stage of the subjects. (AU)
Articles published in Agência FAPESP Newsletter about the research grant:
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DA SILVA, RODRIGO FERNANDES;
CARDOZO, DANIELA MAIRA;
LIBANIO RODRIGUES, GISELE OLINTO;
DE SOUZA-ARAUJO, CAROLINE NATANIA;
MIGITA, NATACHA AZUSSA;
LUCCI DE ANGELO ANDRADE, LILIANA APARECIDA;
YUNES, JOSE ANDRES;
CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.
NOV 13 2017.
Web of Science Citations: 0.